ELDN
Eledon Pharmaceuticals, Inc.
Biotechnology
Market Cap$231M
5Y Perf.-85.2%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ELDN vs PRAX vs ACAD vs ARVN
Revenue, margins, valuation, and 5-year total return — side by side.
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$9.63B
5Y Perf.-37.1%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.86B
5Y Perf.-51.8%
ARVN
Arvinas, Inc.
Biotechnology
Market Cap$652M
5Y Perf.-51.6%
ELDN vs PRAX vs ACAD vs ARVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ELDN | PRAX | ACAD | ARVN |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $231M | $9.63B | $3.86B | $652M |
| Revenue (TTM) | $0.00 | $-92K | $1.10B | $263M |
| Net Income (TTM) | $-80M | $-327M | $376M | $-81M |
| Gross Margin | — | — | 91.5% | 99.5% |
| Operating Margin | — | — | 7.4% | -44.0% |
| Forward P/E | — | — | 55.6x | — |
| Total Debt | $641K | $110K | $52M | $9M |
| Cash & Equiv. | $23M | $357M | $178M | $143M |
ELDN vs PRAX vs ACAD vs ARVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ELDN
PRAX
ACAD
ARVN
| Stock | Oct 20 | May 26 | Return |
|---|---|---|---|
| Eledon Pharmaceutic… (ELDN) | 100 | 14.8 | -85.2% |
| Praxis Precision Me… (PRAX) | 100 | 62.9 | -37.1% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 48.2 | -51.8% |
| Arvinas, Inc. (ARVN) | 100 | 48.4 | -51.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ELDN vs PRAX vs ACAD vs ARVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACAD leads in 2 of 6 categories, making it the strongest pick for profitability and margin quality and operational efficiency and capital deployment. Eledon Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion. PRAX and ARVN also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
ELDN
Eledon Pharmaceuticals, Inc.
The Growth Leader
ELDN is the #2 pick in this set and the best alternative if growth is your priority.
- 100.0% revenue growth vs PRAX's -100.0%
Best for: growth
PRAX
Praxis Precision Medicines, Inc.
The Long-Run Compounder
PRAX is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- -20.1% 10Y total return vs ACAD's -22.9%
- Lower volatility, beta 1.55, Low D/E 0.0%, current ratio 10.22x
- +7.7% vs ELDN's +28.7%
Best for: long-term compounding and sleep-well-at-night
ACAD
ACADIA Pharmaceuticals Inc.
The Growth Play
ACAD carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 11.9%, EPS growth 68.4%, 3Y rev CAGR 27.5%
- 34.3% margin vs ARVN's -30.8%
- 26.2% ROA vs ELDN's -52.0%
Best for: growth exposure
ARVN
Arvinas, Inc.
The Income Pick
ARVN is the clearest fit if your priority is income & stability and defensive.
- beta 1.15
- Beta 1.15, current ratio 4.92x
- Beta 1.15 vs ELDN's 1.92
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ELDN | 100.0% revenue growth vs PRAX's -100.0% |
| Quality / Margins | ACAD | 34.3% margin vs ARVN's -30.8% |
| Stability / Safety | ARVN | Beta 1.15 vs ELDN's 1.92 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PRAX | +7.7% vs ELDN's +28.7% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs ELDN's -52.0% |
ELDN vs PRAX vs ACAD vs ARVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
FY 2018
FY 2025
ELDN vs PRAX vs ACAD vs ARVN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGELDN
Who Leads Where
ACAD leads in 2 of 6 categories
ARVN leads 1 • PRAX leads 1 • ELDN leads 0 • 1 tied
Explore the data ↓ELDNEledon Pharmaceutical…
0leads
ARVNArvinas, Inc.
1leads
PRAXPraxis Precision Medi…
1leads
ACADACADIA Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs PRAXvs ARVNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD4/6
Valuation MetricsMultiples, price ratios, and targets
ARVN2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD and PRAX operate at a comparable scale, with $1.1B and -$92,000 in trailing revenue. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to ARVN's -30.8%. On growth, ACAD holds the edge at +9.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ELDNEledon Pharmaceut… | PRAXPraxis Precision … | ACADACADIA Pharmaceut… | ARVNArvinas, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | -$92,000 | $1.1B | $263M |
| EBITDAEarnings before interest/tax | -$67M | -$357M | $96M | -$111M |
| Net IncomeAfter-tax profit | -$80M | -$327M | $376M | -$81M |
| Free Cash FlowCash after capex | -$67M | -$283M | $212M | -$276M |
| Gross MarginGross profit ÷ Revenue | — | — | +91.5% | +99.5% |
| Operating MarginEBIT ÷ Revenue | — | — | +7.4% | -44.0% |
| Net MarginNet income ÷ Revenue | — | — | +34.3% | -30.8% |
| FCF MarginFCF ÷ Revenue | — | — | +19.4% | -105.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +9.7% | -84.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +28.1% | +2.7% | -81.8% | -65.1% |
ACAD leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
ARVN leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ELDNEledon Pharmaceut… | PRAXPraxis Precision … | ACADACADIA Pharmaceut… | ARVNArvinas, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $231M | $9.6B | $3.9B | $652M |
| Enterprise ValueMkt cap + debt − cash | $209M | $9.3B | $3.7B | $517M |
| Trailing P/EPrice ÷ TTM EPS | -0.13x | -24.72x | 9.85x | -7.96x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 55.62x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 26.91x | — |
| Price / SalesMarket cap ÷ Revenue | — | — | 3.61x | 2.48x |
| Price / BookPrice ÷ Book value/share | 3.90x | 8.54x | 3.15x | 1.52x |
| Price / FCFMarket cap ÷ FCF | — | — | 36.74x | — |
ARVN leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-85 for ELDN. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACAD's 0.04x. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs ELDN's 2/9, reflecting solid financial health.
| Metric | ELDNEledon Pharmaceut… | PRAXPraxis Precision … | ACADACADIA Pharmaceut… | ARVNArvinas, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -85.3% | -43.0% | +35.6% | -14.3% |
| ROA (TTM)Return on assets | -52.0% | -40.2% | +26.2% | -9.3% |
| ROICReturn on invested capital | — | -65.0% | +10.0% | -22.4% |
| ROCEReturn on capital employed | — | -49.3% | +10.1% | -16.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.00x | 0.04x | 0.02x |
| Net DebtTotal debt minus cash | -$22M | -$357M | -$126M | -$134M |
| Cash & Equiv.Liquid assets | $23M | $357M | $178M | $143M |
| Total DebtShort + long-term debt | $641,000 | $110,000 | $52M | $9M |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | — |
ACAD leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACAD five years ago would be worth $10,710 today (with dividends reinvested), compared to $1,601 for ARVN. Over the past 12 months, PRAX leads with a +775.0% total return vs ELDN's +28.7%. The 3-year compound annual growth rate (CAGR) favors PRAX at 174.9% vs ARVN's -25.5% — a key indicator of consistent wealth creation.
| Metric | ELDNEledon Pharmaceut… | PRAXPraxis Precision … | ACADACADIA Pharmaceut… | ARVNArvinas, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +138.3% | +16.4% | -13.7% | -11.2% |
| 1-Year ReturnPast 12 months | +28.7% | +775.0% | +52.4% | +52.8% |
| 3-Year ReturnCumulative with dividends | +39.9% | +1976.5% | +4.7% | -58.7% |
| 5-Year ReturnCumulative with dividends | -56.4% | -20.8% | +7.1% | -84.0% |
| 10-Year ReturnCumulative with dividends | -99.7% | -20.1% | -22.9% | -36.5% |
| CAGR (3Y)Annualised 3-year return | +11.8% | +174.9% | +1.5% | -25.5% |
PRAX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PRAX and ARVN each lead in 1 of 2 comparable metrics.
Risk & Volatility
ARVN is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than ELDN's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 93.6% from its 52-week high vs ARVN's 70.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ELDNEledon Pharmaceut… | PRAXPraxis Precision … | ACADACADIA Pharmaceut… | ARVNArvinas, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.81x | 1.40x | 1.11x | 0.99x |
| 52-Week HighHighest price in past year | $4.60 | $356.00 | $27.81 | $14.51 |
| 52-Week LowLowest price in past year | $1.35 | $35.18 | $14.45 | $5.90 |
| % of 52W HighCurrent price vs 52-week peak | +83.9% | +93.6% | +81.1% | +70.2% |
| RSI (14)Momentum oscillator 0–100 | 62.1 | 55.6 | 44.2 | 42.6 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 378K | 1.8M | 808K |
Evenly matched — PRAX and ARVN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ELDN as "Buy", PRAX as "Buy", ACAD as "Buy", ARVN as "Buy". Consensus price targets imply 64.7% upside for PRAX (target: $549) vs 27.6% for ARVN (target: $13).
| Metric | ELDNEledon Pharmaceut… | PRAXPraxis Precision … | ACADACADIA Pharmaceut… | ARVNArvinas, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $5.00 | $548.80 | $34.78 | $13.00 |
| # AnalystsCovering analysts | 4 | 16 | 37 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +14.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ARVN leads in 1 (Valuation Metrics). 1 tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 2 of 6 categories
Loading custom metrics...
ELDN vs PRAX vs ACAD vs ARVN: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ELDN or PRAX or ACAD or ARVN a better buy right now?
For growth investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate Eledon Pharmaceuticals, Inc. (ELDN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ELDN or PRAX or ACAD or ARVN?
Over the past 5 years, ACADIA Pharmaceuticals Inc.
(ACAD) delivered a total return of +7. 1%, compared to -84. 0% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: PRAX returned -20. 9% versus ELDN's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ELDN or PRAX or ACAD or ARVN?
By beta (market sensitivity over 5 years), Arvinas, Inc.
(ARVN) is the lower-risk stock at 0. 99β versus Eledon Pharmaceuticals, Inc. 's 1. 81β — meaning ELDN is approximately 84% more volatile than ARVN relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 4% for ACADIA Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ELDN or PRAX or ACAD or ARVN?
By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.
(ACAD) is pulling ahead at 11. 9% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -37. 3% for Eledon Pharmaceuticals, Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ELDN or PRAX or ACAD or ARVN?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus -30. 8% for Arvinas, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -43. 8% for ARVN. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ELDN or PRAX or ACAD or ARVN more undervalued right now?
Analyst consensus price targets imply the most upside for PRAX: 64.
7% to $548. 80.
07Which pays a better dividend — ELDN or PRAX or ACAD or ARVN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ELDN or PRAX or ACAD or ARVN better for a retirement portfolio?
For long-horizon retirement investors, Arvinas, Inc.
(ARVN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 99)). Eledon Pharmaceuticals, Inc. (ELDN) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ARVN: -37. 0%, ELDN: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ELDN and PRAX and ACAD and ARVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ELDN is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; ARVN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.